Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria (PKU); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products. It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Period	ROE
2018-12-31	-48.44%
2019-12-31	-173.65%
2020-12-31	-178.57%
2021-12-31	-11.09%
2022-12-31	-68.98%
2023-12-31	-6.05%
2024-12-31	-15.65%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ETON	$26.35	+5.15%	0.36M
3
4
5

Eton Pharmaceuticals Inc. (ETON) Return on Equity (ROE)

ROE & ROA Data

Get Eton Pharmaceuticals Inc. Data in Excel

More ETON Financial Data